Glaukos (NYSE: GKOS) director sells shares after option exercise
Glaukos director Gilbert H. Kliman exercised stock options for 2,500 shares at $25.77 each and subsequently sold all 2,500 shares at $190.00 per share on August 19, 2026. After these transactions, Kliman retains stock options for 12,500 shares and holds 2,501 restricted stock units. The sale generated approximately $475,000 in gross proceeds, with a pre-tax spread of about $411,000.
GKOS Stock Surges 67% Year to Date: What's Driving the Rally?
Glaukos (GKOS) stock has surged 67% year-to-date, significantly outperforming its industry, driven by strong adoption of iDose TR and the successful launch of Epioxa. The company's revenue jumped 49.5% in Q2, leading to an increased 2026 revenue guidance. While the company is expanding its ophthalmology platform and pipeline, investors should consider execution risks related to reimbursement, competition, and new product launches despite the positive growth outlook.
Glaukos Corp stock hits all-time high at 190.27 USD
Glaukos Corp's stock has reached an all-time high of $190.27, following a 111.6% increase over the past year and a significant revenue growth of 41.55% in the last twelve months. This surge is attributed to strong Q2 2026 financial results, which surpassed Wall Street expectations, leading to upward revisions in price targets from several analyst firms. Despite its strong performance, InvestingPro analysis suggests the stock is currently overvalued.
Glaukos (GKOS) Reports Q2 Loss, Tops Revenue Estimates
Glaukos (GKOS) reported a smaller-than-expected Q2 loss of $0.14 per share, surpassing the Zacks Consensus Estimate of a $0.28 loss. The company also exceeded revenue expectations, posting $185.61 million against a consensus of $149.57 million. Despite outperforming the market year-to-date, the stock currently holds a Zacks Rank #4 (Sell) due to unfavorable estimate revisions.
Glaukos (NYSE:GKOS) Reaches New 12-Month High - Should You Buy?
Glaukos (NYSE:GKOS) recently hit a new 52-week high of $190.06, reaching an $11.19 billion market capitalization. Despite a "Moderate Buy" consensus from analysts, their average price target of $177.33 is below the current share price. The company reported better-than-expected quarterly results, with revenue up 49.6% year-over-year, although insiders have sold approximately $19.1 million in stock over the last three months.
Glaukos (NYSE: GKOS) holder to sell 2,500 shares in 2026
A Glaukos (NYSE: GKOS) shareholder, Gilbert H. Kliman, plans to sell 2,500 shares of common stock on or after August 19, 2026, through Fidelity Brokerage Services LLC on the NYSE. The aggregate market value of these shares is $475,000, and the sale is associated with a stock option exercise. This information was disclosed in a Form 144 SEC filing, which outlines conditions for reselling restricted or insider-held shares.
Here's Why You Should Retain Glaukos Stock in Your Portfolio for Now
Glaukos Corporation (GKOS) is identified as a stock to retain due to strong growth prospects from its iDose TR and Epioxa franchises, leading to an increased sales outlook and margin expansion. Despite potential challenges like Medicare coverage uncertainty for iDose and temporary revenue volatility for Epioxa, the company's diversified pipeline across various ophthalmic therapeutic platforms supports long-term growth. Glaukos has demonstrated strong financial performance, with significant earnings surprises and positive stock performance year-to-date.
145,202 Shares in Glaukos Corporation $GKOS Bought by TimesSquare Capital Management LLC
TimesSquare Capital Management LLC has acquired 145,202 shares of Glaukos Corporation (NYSE:GKOS) worth approximately $20.3 million, representing a 0.25% stake in the medical instruments supplier. This comes as Glaukos reported strong quarterly revenue growth of 49.6% year over year, reaching $185.6 million, and institutional investors collectively own 99.04% of the company's stock. Despite significant insider selling totaling $19.1 million over the past three months, analysts maintain a "Moderate Buy" rating with a consensus price target of $177.33.
Glaukos Market Cap More Than Doubles in a Year to $11B
Glaukos Corp.'s market capitalization has surged to over $11 billion, more than double its value from a year ago, driven by investor confidence in its expansion beyond glaucoma into new areas of eye care. The Aliso Viejo-based company reported record second-quarter net sales of $185.6 million, a 50% year-over-year increase, and raised its full-year guidance. This growth is supported by the success of its iDose TR glaucoma implant and new therapies like Epioxa for keratoconus, along with ventures into treatments for Demodex blepharitis.
Oppenheimer Asset Management Inc. Invests $2.73 Million in Glaukos Corporation $GKOS
Oppenheimer Asset Management Inc. recently acquired a new stake of 19,564 shares in Glaukos Corporation, valued at approximately $2.73 million, during the second quarter. This move comes as institutional investors collectively own 99.04% of Glaukos, a medical instruments supplier that recently reported better-than-expected quarterly results with significant revenue growth. Despite strong institutional interest and positive analyst ratings, insiders have sold a considerable amount of stock, totaling $19.1 million over the past three months.
3 Stocks That May Be Trading Below Their Estimated Value By Up To 50%
This article identifies three US stocks—Datadog (DDOG), Super Micro Computer (SMCI), and Glaukos (GKOS)—that appear to be trading significantly below their estimated fair value based on future cash flow analyses. Despite market resilience and projected earnings growth, these companies show potential for investors seeking discounted opportunities, with Glaukos estimated to be undervalued by as much as 50%. The report provides an overview of each company's operations, financial performance, and estimated discount, while acknowledging potential risks like insider selling or legal challenges.
Walleye Capital LLC Takes $3.75 Million Position in Glaukos Corporation $GKOS
Walleye Capital LLC has acquired a new stake of $3.75 million in Glaukos Corporation (NYSE:GKOS) during the second quarter, making it one of many institutional investors holding 99.04% of the company's stock. Glaukos reported better-than-expected quarterly results with significant revenue growth, and analysts maintain a "Moderate Buy" rating despite recent insider share sales totaling over $19.1 million. The company is a medical technology firm focusing on micro-invasive glaucoma surgery (MIGS) and sustained drug-delivery solutions for eye diseases.
Glaukos President, COO Joseph E. Gilliam disposes of 60,000 shares worth $10.82 million
Joseph E. Gilliam, President and COO of Glaukos, sold 60,000 shares of common stock on August 11, 2026, for approximately $10.82 million. The shares were sold at weighted average prices of $178.89 and $180.49, after Gilliam exercised options for the same number of shares at lower prices. Following the transaction, his stake in Glaukos common stock was reduced to 72,588 shares.
Glaukos Insider Sold Shares Worth $10,784,659, According to a Recent SEC Filing
An insider at Glaukos Corporation (GKOS) recently sold shares valued at $10,784,659, as reported in a recent SEC filing. This transaction comes amidst various analyst target price adjustments and the company's Q2 2026 earnings release, which showed narrower adjusted losses and increased revenue. Glaukos, an ophthalmic pharmaceutical and medical technology company, specializes in treatments for glaucoma, corneal disorders, and retinal diseases.
Insider Selling: Glaukos (NYSE:GKOS) COO Sells 60,000 Shares of Stock
Glaukos Corporation's COO, Joseph Gilliam, sold 60,000 shares of company stock for approximately $10.8 million, reducing his direct ownership by 45.25%. The sale occurred while Glaukos shares were trading near a 52-week high, and the company recently reported strong quarterly revenue and beat EPS estimates. Despite the insider selling, analyst sentiment remains largely positive, with a "Moderate Buy" consensus and several raised price targets.
Glaukos COO Joseph Gilliam sells $10.7m in stock
Glaukos Corporation's COO, Joseph Gilliam, sold 60,000 shares of company stock for $10.7 million after exercising stock options. These sales occurred when the stock was near its 52-week high, and Gilliam now beneficially owns 72,588 shares. The transactions follow recent strong Q2 2026 financial results for Glaukos, which led to increased price targets from several analyst firms.
Glaukos (GKOS) Is Up 6.7% After Raising 2026 Sales Guidance And Narrowing Quarterly Loss
Glaukos Corporation (GKOS) stock increased by 6.7% after the company reported narrowing quarterly losses and raised its 2026 net sales guidance to between US$680 million and US$700 million. This improved outlook, partly driven by a new CMS J code for Epioxa, reinforces confidence in revenue growth for its glaucoma and corneal therapies, though the company remains loss-making. Analysts project Glaukos to reach $1.1 billion in revenue and $113.0 million in earnings by 2029.
Glaukos (GKOS) Is Up 6.7% After Raising 2026 Sales Guidance And Narrowing Quarterly Loss
Glaukos (GKOS) shares rose 6.7% after the company increased its 2026 net sales guidance to US$680 million to US$700 million and narrowed its quarterly loss per share to US$0.31. This positive adjustment follows strong Q2 2026 sales of US$185.61 million and the introduction of a new CMS J code for its Epioxa therapies, which is expected to simplify billing and reimbursement. Despite the improved revenue outlook, the article highlights the ongoing challenge of the company being loss-making and reliant on supportive reimbursement policies.
Glaukos Corp stock hits all-time high at 184.45 USD
Glaukos Corp (GKOS) stock has reached an all-time high of $184.45, reflecting a 100.01% increase over the past year and a 41.55% revenue surge in Q2 2026. Despite an InvestingPro analysis suggesting the stock may be overvalued, 11 analysts have revised earnings upwards, indicating continued optimism. The company also reported strong Q2 2026 financial results, exceeding analyst expectations and leading several firms to raise their price targets.
Glaukos SVP & CFO Alex Thurman sells $3.6m in GKOS stock
Alex R. Thurman, SVP and CFO of Glaukos Corp, sold 20,000 shares of GKOS stock for approximately $3.6 million, while also exercising stock options for 20,000 shares. These transactions were performed under a Rule 10b5-1 trading plan. The sale comes as Glaukos stock trades near its 52-week high, and the company recently reported strong Q2 2026 results, leading to multiple analyst price target increases.
Glaukos (GKOS) Is Up 6.7% After Raising 2026 Sales Guidance And Narrowing Quarterly Loss
Glaukos (GKOS) reported strong second-quarter 2026 results, with sales increasing to US$185.61 million and a narrowed basic loss per share. The company raised its full-year 2026 net sales guidance to US$680 million to US$700 million, reflecting increased confidence in its revenue outlook. A new CMS J code for Epioxa and Epioxa HD is expected to support the uptake of its newer therapies, though reimbursement and pricing pressures remain key risks.
Insider Selling: Glaukos (NYSE:GKOS) CFO Sells 20,000 Shares of Stock
Glaukos CFO Alex Thurman sold 20,000 shares of GKOS stock for $3.6 million on August 7th, reducing his direct holdings by 31.3%. The sale was executed under a pre-arranged Rule 10b5-1 trading plan. Despite the insider sale, Glaukos stock recently traded up 0.9% to $182.97, near its 52-week high, following strong quarterly results that beat analyst expectations.
GLAUKOS Corp SEC Filing (Aug 11, 2026)
GLAUKOS Corp (GKOS) filed a Form 144 with the SEC on August 11, 2026, indicating a proposed sale of 60,000 shares of common stock acquired through a stock option exercise on the same date. The aggregate market value of these shares is $10,784,645.13, and they are to be sold via Fidelity Brokerage Services LLC on the NYSE. The filing represents a neutral impact and sentiment according to AI-generated analysis.
Assenagon Asset Management S.A. Has $15.20 Million Stock Position in Glaukos Corporation $GKOS
Assenagon Asset Management S.A. significantly increased its stake in Glaukos Corporation (NYSE:GKOS) by 932.5% in the second quarter, now holding 108,736 shares valued at approximately $15.2 million. Glaukos reported strong Q2 earnings with a 49.6% revenue increase year-over-year and beat analyst EPS expectations, though company insiders sold $5.44 million worth of stock in the last 90 days. Analysts maintain a "Moderate Buy" rating for GKOS, with an average price target of $177.33.
How (GKOS) Movements Inform Risk Allocation Models
This article analyzes Glaukos Corporation (NASDAQ: GKOS) using AI models, identifying strong sentiment across all horizons and suggesting an overweight bias. It outlines three distinct institutional trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels for different risk profiles. The analysis also provides multi-timeframe signal strengths, support, and resistance levels.
Glaukos (GKOS) Q2 2026 Earnings Call Transcript
Glaukos (GKOS) reported record second-quarter 2026 net sales of $185.6 million, a 50% increase year-over-year, driven by strong adoption of iDose TR and the launch of Epioxa. The company raised its full-year 2026 net sales guidance to $680 million to $700 million and provided updated guidance for its various segments, including a 20% growth target for Corneal Health and 50% for U.S. Glaucoma. Management highlighted ongoing investments in its pipeline and commercial infrastructure, maintaining a focus on disciplined capital allocation despite anticipated near-term volatility in the Corneal Health segment due to J-code transitions.
Glaukos Corporation (GKOS) Stock Analysis: Target Price Insights And Growth Prospects
Glaukos Corporation (GKOS) is a prominent healthcare company specializing in medical devices for eye disorders, currently priced at $180.02. Despite a high forward P/E ratio of 358.64 and negative profitability metrics, the company shows robust revenue growth of 49.50% and strong analyst sentiment with a target price of $193.62. Its innovative product portfolio and growth-focused strategy make it a compelling opportunity for investors seeking exposure to medical technology, though caution is advised due to its valuation and unprofitability.
Dimensional Fund Advisors LP Sells 6,377 Shares of Glaukos Corporation $GKOS
Dimensional Fund Advisors LP has reduced its stake in Glaukos Corporation (NYSE:GKOS) by 3.1%, selling 6,377 shares and retaining 199,084 shares valued at approximately $21.4 million. Despite this, institutional investors collectively own 99.04% of Glaukos's stock, and analysts maintain a "Moderate Buy" rating with an average price target of $177.33. The company recently exceeded quarterly earnings expectations, reporting revenue of $185.6 million and an adjusted loss per share of $0.14, better than the anticipated $0.21 loss.
A Look at Glaukos Corp (GKOS) After 5.3% Gain -- GF Value $147.7
Glaukos Corp (GKOS) recently saw a 5.3% stock gain, closing at $180.02, but GuruFocus assesses it as 21.8% overvalued with a GF Value of $147.78. Despite a strong GF Score™ of 78/100 and high growth potential (9/10), the company faces significant challenges with low profitability (3/10) and is currently loss-making and cash-flow negative. Insider selling of $6.4 million in the last three months, with no buying activity, further raises concerns about the stock's current valuation and future prospects.
Glaukos (NYSE: GKOS) insider Alex R. Thurman plans 20,000-share stock sale
Glaukos Corporation insider Alex R. Thurman has filed a Form 144 to sell 20,000 common shares, valued at approximately $3.6 million, stemming from a stock option exercise on August 7, 2026. This proposed sale follows three previous sales by Thurman in the past three months, each for 10,000 shares, totaling over $4.6 million in proceeds. The filing provides key details about the transaction and the company's outstanding shares.
Glaukos completes enrollment in PRESERFLO MicroShunt pivotal study
Glaukos Corporation has completed patient enrollment in its U.S. pivotal clinical study for the PRESERFLO MicroShunt, a device designed to lower intraocular pressure in adult patients with primary open-angle glaucoma. The study aims to support a potential 510(k) clearance from the FDA, evaluating a 20% reduction in mean diurnal IOP from baseline. The PRESERFLO MicroShunt has already received regulatory approval in Canada and Australia and has demonstrated favorable outcomes compared to trabeculectomy in previous evaluations, including lower rates of adverse events.
Insider Selling: Glaukos (NYSE:GKOS) Director Sells $88,005.75 in Stock
Glaukos Corporation Director Leana Wen sold 525 shares of GKOS stock for $88,005.75 on July 31st, reducing her stake by 2.43%. Despite the insider sale, Glaukos shares rose to $170.90, nearing their 52-week high, following a strong quarterly earnings report that exceeded analyst expectations. The company maintains a "Moderate Buy" consensus rating from analysts, with institutional investors holding a significant 99.04% of the stock.
Glaukos publishes investor presentation highlighting interventional glaucoma, keratoconus pipeline programs
Glaukos presented its investor strategy focusing on interventional glaucoma to reduce reliance on topical drops, citing high non-compliance rates. Key products include iDose TR, a long-duration travoprost implant, and Epioxa, an FDA-cleared epithelium-on cross-linking therapy for keratoconus. The presentation highlighted clinical metrics for iDose TR and ongoing pipeline development for next-generation iDose devices.
Glaukos (NYSE: GKOS) insider plans sale of 525 vested shares
An insider at Glaukos Corporation (NYSE: GKOS), Leana Wen, plans to sell 525 vested shares of common stock with an aggregate market value of $88,005.75 around July 31, 2026. These shares are compensation from restricted stock that vested on May 30, 2025. Wen previously sold 1,700 shares on May 1, 2026, totaling $247,095.17.
Glaukos Corporation Stock 12‑Month Price Target Raised to $193.62, Implies 20% Upside
Glaukos Corporation (GKOS) has received a raised 12-month average price target of $193.62 from 13 analysts, up from $163.85. This new target implies a potential upside of approximately 20% from its July 29 closing price. The consensus rating for GKOS remains a "Buy" among 14 covering analysts.
Stifel raises Glaukos stock price target to $190 on revenue outlook
Stifel raised its price target on Glaukos Corporation (NYSE:GKOS) to $190 from $175, maintaining a Buy rating, based on positive surveys for iDose and Epioxa and a strong revenue outlook, projecting $1.0 billion or more in 2027. This follows Glaukos exceeding Q2 2026 earnings expectations with record net sales, leading other analysts like Needham and Truist Securities to also raise their price targets. Despite the stock's 72% surge, InvestingPro suggests the shares might be overvalued.
Glaukos Corp stock hits 52-week high at 161.67 USD
Glaukos Corp (GKOS) stock recently reached a 52-week high of $161.67, with a year-to-date return of 34% and a 70.14% increase over the past year. Despite this strong performance, InvestingPro analysis indicates the stock may be overvalued relative to its Fair Value. The company also announced the completion of patient enrollment for its Phase 2 clinical study of GLK-321, and analysts from Stifel, Piper Sandler, and William Blair have reiterated ratings with varied price targets for its products like iDose and Epioxa.
Needham raises Glaukos stock price target to $201 on guidance boost
Needham has increased its price target for Glaukos Corporation (NYSE:GKOS) to $201 from $150, maintaining a Buy rating, following the company's strong Q2 2026 revenue performance. Glaukos exceeded consensus estimates, driven by iDose and Epioxa, leading management to raise its 2026 revenue guidance by 10%. Another firm, Truist Securities, also raised its target to $215, further highlighting the company's robust performance and optimistic outlook.
Glaukos Corporation Stock 12‑Month Price Target Raised to $178.23, Implies 10% Upside
Glaukos Corporation's average stock price target has been increased from $163.85 to $178.23 by 13 analysts, suggesting a 10% potential upside from its Jul. 29 closing price. The consensus rating remains a "Buy" from 14 analysts, with 13 recommending a Buy and 1 a Hold.
GLAUKOS Corp Q2 2026: Revenue $185.6M, EPS $(0.31) — 10-Q Summary
GLAUKOS Corp reported its second-quarter 2026 results, showing a significant increase in revenue to $185.6M, up 50% year-over-year from $124.1M. Although the company still posted a net loss of $18.4M, the diluted net loss per share improved to $(0.31) from $(0.34) in the prior-year quarter. Key drivers for growth included higher iDose TR and Epioxa volumes, a shift towards ambulatory surgery center procedures, and the commercial rollout of Epioxa with a new HCPCS code.
Glaukos Corporation (GKOS) Stock Rises on Q2 2026 Earnings
Glaukos Corporation (GKOS) reported Q2 2026 revenue of $185.6 million, an increase of 49.5% year-over-year, surpassing Wall Street expectations. Despite strong revenue growth, the company recorded an operating loss of $17.3 million and a net loss of $18.4 million, or -$0.31 per diluted share. Investors reacted positively, with the stock rising 1.93% after market close, indicating a focus on revenue performance over persistent profitability challenges.
Earnings Flash (GKOS) Glaukos Corporation Posts Q2 Adjusted Loss $0.14 per Share, vs. FactSet Est of $-0.21
Glaukos Corporation (GKOS) reported a Q2 adjusted loss of $0.14 per share, which is better than FactSet's estimated loss of $0.21 per share. The company also announced strong Q2 revenue of $185.6 million, significantly exceeding FactSet's estimate of $150.9 million, and expects 2026 net sales between $680 million and $700 million. This financial update indicates a positive performance relative to analyst expectations for the ophthalmic pharmaceutical and medical technology company.
Glaukos Number of Employees 2026 | Employee Count & Headcount Data
Glaukos Corp. (GKOS) has grown its total workforce to 1,138 employees worldwide as of March 2026, marking a 24.2% increase from 2023. The company is actively hiring with 89 job postings in 2026 and its workforce is primarily concentrated in the United States, with Germany showing the fastest growth in employee count. The average employee salary at Glaukos is $151,827, with variations across different regions.
Glaukos Corp (GKOS) Risk Assessment: Volatility, Financial Risk & Investment Risk
This article provides a risk assessment for Glaukos Corp (GKOS), noting its current risk assessment score of 5.96 and its ranking within the Healthcare Equipment & Supplies industry. It details various risk metrics including the company's beta value of 0.86, suggesting lower volatility compared to the S&P 500, and provides data on VaR, maximum drawdown, volatility, and Sharpe ratios over different periods. The analysis also touches on liquidity and turnover rates.
Glaukos: A Further Guidance Hike On Revenues Could Spike Shares Post Q2 Release (GKOS)
Glaukos (GKOS) shares are approaching technical resistance near $160 ahead of its Q2 earnings release, maintaining a "Hold" rating. Strong revenue growth, with a 91% stock rally since last year, is driven by Q1's 41%+ and Q3's 38% YoY growth. Key factors for a potential spike include Q2 revenue outperformance, a guidance hike above $640 million, and successful adoption of Epioxa and iDose TR.
Stifel reiterates Glaukos stock rating on Epioxa demand strength
Stifel maintained a Buy rating and a $175 price target for Glaukos Corporation (NYSE:GKOS) due to the strong intermediate-to-long-term prospects of its Epioxa drug, supported by robust early demand identified through ophthalmologist surveys. The firm projects significant market growth and peak sales of $1.5 billion for Epioxa, doubling its current 2027-2028 sales estimates. Despite the company not yet being profitable, revenue is surging, and analyst interest continues with updates on other key products like iDose and GLK-321.
Glaukos Announces Completion of Patient Enrollment in 510(k) Pivotal Study for PRESERFLO™ MicroShunt
Glaukos Corporation announced the completion of patient enrollment in its U.S. 510(k) pivotal study for the PRESERFLO™ MicroShunt. This device is designed to treat primary open-angle glaucoma in patients who have not responded to previous medical and surgical treatments. The company aims to use these study results to support a future FDA marketing submission, potentially offering a crucial new option for patients at risk of vision loss.
Glaukos completes enrollment in pivotal trial of PRESERFLO MicroShunt for treatment-resistant glaucoma
Glaukos Corporation has successfully completed patient enrollment for its US pivotal study of the PRESERFLO MicroShunt, a device designed to treat advanced glaucoma in patients who have not responded to prior incisional or cilioablative surgeries. The trial included over 110 patients across the US and Canada who remained inadequately controlled on IOP-lowering medications. This milestone initiates the 12-month follow-up period, with topline data expected no earlier than mid-2027, which Glaukos intends to use for an FDA marketing submission.
Glaukos Corp Revenue Breakdown – BX:GKOS
Glaukos Corporation (BX:GKOS) generated 402.28 million CHF last year, with its Glaucoma segment being the top performer, contributing 333.81 million CHF. The United States was the largest geographical contributor, accounting for 297.32 million CHF of the company's revenue. This financial data highlights the company's primary revenue streams and key markets.
Glaukos completes enrollment with at least 110 glaucoma patients
Glaukos Corporation announced the completion of patient enrollment in its U.S. 510(k) pivotal study for the PRESERFLO MicroShunt, a device designed to lower intraocular pressure in patients with primary open-angle glaucoma who had previous unsuccessful treatments. The study enrolled at least 110 patients and aims for a 20% or greater reduction in mean diurnal IOP from baseline at 12 months. Glaukos plans to use these results for a future FDA marketing submission for the device.
